亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

鄭州荔諾生物科技有限公司  

天然植物提取物、化妝品原料、化工中間體、膳食補充劑

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:周凱
  • 電話:0371-60332380
  • 郵件:lionbest@126.com
  • 傳真:0371-55038055
  • QQ:951570747
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > ***吡格列酮
***吡格列酮
單價 面議對比
詢價 暫無
發貨 河南鄭州市付款后24小時內
過期 長期有效
更新 2014-09-03 17:57
 
詳細信息
 
***吡格列酮
 
產品名稱:吡格列酮
 
英文名:Pioglitazone hydrochloride
 
別名:[5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-]thiazolidinedione hydrochloride
 
中文化學名:5-{4-[2-(5-乙基-2-吡啶)-乙氧基]-苯基}-2,4-噻唑烷二酮***
 
分子式  C19H20N2O3S.HCl
 
分子量  392.90
 
CAS 登錄號  112529-15-4
 
分子結構式:
 
                           
 
 
含量:≥99.0%
 
性狀:白色或類白色結晶粉末
 
功效:改善和控制血糖,是最新的治療II型糖尿病藥。
 
 
產品包裝:(紙板桶或鋁箔滅菌包裝)也可按照客戶要求包裝。

©2025 鄭州荔諾生物科技有限公司 版權所有   技術支持:化工網   訪問量:7243  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |